Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ColonScan

Financiado

A simple to use accurate and cost effective blood test for large scale colon ca...

A simple to use accurate and cost effective blood test for large scale colon cancer screening Universal Diagnostics (UDX) is a biomedicine start-up focused on early detection of cancer using leading-edge technologies. Our mission is to make cancer a curable disease by detecting it early through an accurate, simple to use,... ver más

30/09/2018

UNIVERSAL DIAGNOST...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

UNIVERSAL DIAGNOSTICS SOCIEDAD ANONIMA No se ha especificado una descripción o un objeto social para esta compañía.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-09-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 100%

2 Participantes

UNIVERSAL DIAGNOSTICS SOCIED...

50.00K€ | Lider

HUMAN-LIKE MACHINES

323.05K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 4 meses Fecha Inicio: 2018-05-04
Fecha Fin: 2018-09-30

Presupuesto del proyecto 71K€

Descripción del proyecto Universal Diagnostics (UDX) is a biomedicine start-up focused on early detection of cancer using leading-edge technologies. Our mission is to make cancer a curable disease by detecting it early through an accurate, simple to use, and cost-effective diagnostic kit. During the last 5 years, UDX has been developing a mass spectrometry (MS) based metabolic analysis that allows very cost-effective and accurate detection of metabolic markers in blood, for early detection of different types of cancer. The first product of the company (the one this proposal is all about) is ColonScan: A simple, noninvasive, accurate (AUC 92%) and inexpensive, blood-based screening test to detect colorectal cancer (CRC) and adenomas (precancerous stages), allowing early detection and cancer prevention. ColonScan will be highly accurate, easily scalable worldwide, simple to use, non-invasive and inexpensive; ColonScan presents all characteristics and requirements to be adopted as CRC screening program for average risk population since, our technology can be included routinely in normal blood tests at annual or biannual medical check-ups. Moreover, the metabolomics platform developed in ColonScan project can be applied and upscaled to other types of cancer with no cost increase. CRC is the third most commonly diagnosed and leading cause of cancer death in the world, despite CRC is considered a completely preventable disease. All CRC guidelines recommends regularly (annual or biannual) screening of average risk population (50-85 years old). This represents a huge market opportunity, which according to our conservative estimations means a target population of 380 Million people and 12 Billion market opportunity. The ultimate objective of ColonScan Phase 1 project is to assess the feasibility of our business innovation project, under a commercial, technical and financial point of view to minimize any potential risk that might endanger our business plan.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores